医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Ossur Announces Establishment of Ossur Japan

2020年09月01日 AM08:00
このエントリーをはてなブックマークに追加


 

REYKJAVIK, Iceland

Ossur, a global leader in prosthetic and non-invasive orthopaedic technologies has announced the establishment of Ossur Japan G.K., a new entity that will be based in Tokyo and fully operational from January 1st, 2021. Ossur Japan will be led by Mrs. Shoko Nireki, who has been leading the Japanese operations for more than 15 years.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200831005198/en/

Signing ceremony for Japan-based Team Ossur members at the Icelandic Embassy in Tokyo (Photo: Business Wire)

Signing ceremony for Japan-based Team Ossur members at the Icelandic Embassy in Tokyo (Photo: Business Wire)

Ossur President and CEO, Jon Sigurdsson said, “For over 20 years, Ossur has been providing our innovative prosthetic and orthopaedic products to help Japanese healthcare professionals help their patients live a life without limitations. Our new operation represents an even greater commitment to the Japanese market, enabling us to further expand our direct activities there, including clinical education programs, sales, service and support, and related marketing activities.”

According to Sigurdsson, Ossur will also continue working with Pacific Supply Co., Ltd., the company’s exclusive prosthetics distributor in Japan as part of a continuing relationship that was first established in 1999. The evolution of this successful partnership exemplifies both parties’ belief that we are stronger together.

“We believe our new efforts will benefit both organizations as we continue working together in advancing our shared mission of helping improve the quality of life and mobility for even more people,” said Kei Kawamura, President and CEO of Pacific Supply Co., Ltd.

About Ossur

Ossur (Nasdaq Copenhagen: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations. A recognized “Technology Pioneer,” Ossur focuses on improving people’s mobility through the delivery of innovative technologies in Prosthetics and Bracing & Supports, by investing significantly in research and product development to create award-winning designs with consistently strong market positions. Successful patient and clinical outcomes are further empowered via Ossur’s educational programs and business solutions. As part of Ossur’s long-standing commitment to social responsibility, the company has been a signatory to the United Nations Global Compact since 2011, and also participates in the Nasdaq Nordic and Baltic exchanges’ voluntary guidelines for Environment, Social and Corporate Governance (ESG). Ossur is headquartered in Iceland, with major operations in the Americas, Europe and Asia, and additional distributors worldwide. www.ossur.com

About Pacific Supply

Pacific Supply is a Japanese trade and wholesale company in medical and welfare devices. Since it was established in 1968, Pacific Supply has distributed sophisticated products and services particularly in orthotic and prosthetic field all over Japan through local reliable partners. As a strong and definitive mission, Pacific Supply focuses on improving people’s quality of life and contributing to progress and development of a society. As one of the most important activities, Pacific Supply puts emphasis on education such as seminars and conferences to support medical professionals such as CPO and therapists to provide best possible solutions to their clients. Pacific Supply is headquartered in Osaka, Japan and has 6 branch offices to operate throughout Japan. https://www.p-supply.co.jp/

View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005198/en/

CONTACT

Further information

Ossur Japan G.K. Contact

Sujit Bedi, Mr. Marketing Manager

sbedi@ossur.com

Pacific Supply Contact

Kazuyuki Hasada Mr. Director / Head of Business Development

hasada@p-supply,co.jp

TEL 81-72-875-8013

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続